Every program is structured in phases so our partners know exactly what to expect.

Project definition
At the start of each project, we quantitatively define with our partner the success criteria for a given compound.

These include goals like freedom-to-operate (FTO), drug-likeness and synthesizability, as well as lead criteria such as in vitro activity, selectivity, and early PK goals.

We also define with our partner, where appropriate, the drug development candidate criteria, which often include toxicity and PK, as well as efficacy in the relevant animal models.

Design delivery and acceptance (months 0–3)
Our platform searches very large virtual libraries designed by our medicinal chemists. Our partners can participate in the library design by either contributing chemistries of interest or by providing input for the Numerate-designed libraries.

These libraries are then searched, without expert intervention, until the set of 12 compounds in each of 3–5 series has been identified.

What follows is a formal "design acceptance" step. Our partner can check the FTO, approve the synthetic budget, and ensure that if the identified compounds are confirmed in the laboratory, they would present a path forward for the program.

Laboratory validation (months 6–12)
Numerate manages the synthesis of the identified compounds and either outsources their screening or delivers them to the partner for screening. Numerate is not a CRO, so this service is charged at cost. Compounds are evaluated against the agreed lead criteria.

Identify the drug development candidate (months 12–24)
At this point, Numerate and the partner run a design > synthesis > validation loop to identify the drug development (clinical) candidate. Lead compounds are evaluated against the drug development candidate criteria to determine the success of each run of the testing loop.